Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic NSCLC Harboring METex14 Mutations

NCT05796726 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05796726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05796726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic NSCLC Harboring METex14 Mutations
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
December 10, 2021
Completion date
March 22, 2022
Enrollment
260 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic non-small cell lung cancer harboring metex14 mutations